Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Research and Markets has announced the addition of the "Coronaviridae Infections - Pipeline Review, H2 2016" report to their offering.
Coronaviridae Infections pipeline therapeutics constitutes close to 31 molecules. Out of which approximately 24 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 13, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.
Coronaviridae Infections - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Coronaviridae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Coronaviridae Infections and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Coronaviridae Infections Overview
- Therapeutics Development
- Pipeline Products for Coronaviridae Infections - Overview
- Pipeline Products for Coronaviridae Infections - Comparative Analysis
- Coronaviridae Infections - Therapeutics under Development by Companies
- Coronaviridae Infections - Therapeutics under Investigation by Universities/Institutes
- Coronaviridae Infections Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Coronaviridae Infections - Products under Development by Companies
- Coronaviridae Infections - Products under Investigation by Universities/Institutes
- Coronaviridae Infections - Companies Involved in Therapeutics Development
- AstraZeneca Plc
- CEL-SCI Corporation
- GeneCure LLC
- Gilead Sciences, Inc.
- Hemispherx Biopharma, Inc.
- Humabs BioMed SA
- Inovio Pharmaceuticals, Inc.
- Kineta, Inc.
- Nanotherapeutics, Inc.
- NanoViricides, Inc.
- Novavax, Inc.
- Organic Vaccines
- Phelix Therapeutics, LLC
- Planet Biotechnology Inc.
- Protein Sciences Corporation
- Regeneron Pharmaceuticals Inc
For more information about this report visit http://www.researchandmarkets.com/research/6ggvlp/coronaviridae
View source version on businesswire.com: http://www.businesswire.com/news/home/20160928005738/en/
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Infectious Diseases Drugs
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!